| Citation: |
CHEN Yu, WU Weili, JIN Feng, LI Yuanyuan, LONG Jinhua, GONG Xiuyun, CHEN Xiaoxiao, HUANG Shiying, ZHOU Ya, TANG Hong. Clinical Observation of Induction Chrono-chemotherapy Followed by Concurrent Lobaplatin Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 689-693. DOI: 10.3971/j.issn.1000-8578.2017.17.0031
|
To observe the efficacy and side effects of induction chrono-chemotherapy combined with concurrent Lobaplatin chemoradiotherapy on locally advanced head and neck squamous cell carcinoma patients.
Thirty patients with locally advanced head and neck squamous cell carcinoma were treated with TPF regimen induction chrono-chemotherapy followed by concurrent lobaplatin chemoradiotherapy.
The median follow-up was performed for 23 months. The effective rate after chemotherapy was 77%. That after simultaneous radiotherapy and chemotherapy was 93%. The overall survival rate, progression-free survival rate, local recurrence-free survival rate and distant metastasis-free survival rates of one year were 83.3%, 83.3%, 89.4% and 96.3%; those of two years were 71.6%, 68.4%, 73.4% and 86%, those of three years were 65.1%, 62.2%, 66.8% and 78.2%, respectively. The main toxicities of introduction chemotherapy were 3-4 grade of platelet reduction in one case, 3-4 grade of white blood cells reduction in seven cases, and 3-4 grade of neutropenia reduction in nine cases. The main toxicities of concurrent chemoradiotherapy were 3-4 grade of oral mucositis in four cases, 3-4 levels of thrombocytopenia in seventeen cases, 3-4 grades of leukopenia in twelve cases and 3-4 grade of neutropenia reduction in ten cases.
The clinical efficacy of TPF regimen induction chrono-chemotherapy combined with concurrent Lobaplatin chemoradiotherapy is good, with tolerated side effects, but still need to expand the number of cases for long-term follow-up study.
| [1] |
Vermorken JB, Remenar E, van Herpen C. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357(17):1695-704. doi: 10.1056/NEJMoa071028
|
| [2] |
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007, 357(17):1705-15. doi: 10.1056/NEJMoa070956
|
| [3] |
李媛媛, 金风, 吴伟莉, 等.时辰诱导化疗序贯同步放化疗治疗局部晚期鼻咽的Ⅱ期临床研究[J].中国肿瘤临床, 2013, 40(15):914-8. doi: 10.3969/j.issn.1000-8179.2013.15.009
Li YY, Jin F, Wu WL, et al. PhaseⅡclinical trial of induction chrono-chemotherapy followed by concurrent chemoradiation in loco-regionally advanced nasopharyngeal carcinoma[J]. Zhongguo Zhong Liu Lin Chuang, 2013, 40(15):914-8. doi: 10.3969/j.issn.1000-8179.2013.15.009
|
| [4] |
Paccagnella A, Ghi MG, Loreqqian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer:a phaseⅡrandomized study[J]. Ann Oncol, 2010, 21(7):1515-22. doi: 10.1093/annonc/mdp573
|
| [5] |
Mizumachi T, Homma A, Kakizaki T, et al. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma[J]. Int J Clin Oncol, 2015, 20(3):431-7. doi: 10.1007/s10147-014-0726-y
|
| [6] |
郭灵, 林焕新, 冼励坚.恶性肿瘤时辰化疗的基础理论及实践[J].中国肿瘤临床, 2004, 31(1):56-9. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL200401019.htm
Guo L, Lin HX, Xian LJ. Basic theory and practice of rhythm chemotherapy for carcinoma[J]. Zhongguo Zhong Liu Lin Chuang, 2004, 31(1):56-9. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL200401019.htm
|
| [7] |
毕婷, 金风, 吴伟莉, 等.诱导化疗不同给药方式治疗鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志, 2015, 37(9):676-81. http://cdmd.cnki.com.cn/Article/CDMD-10246-1013102698.htm
Bi T, Jin F, Wu WL, et al. Phase Ⅱ clinical trial of two different modes of administration of the induction of the induction chemotherapy for locally advanced nasopharyngeal carcinoma[J]. Zhonghua Zhong Liu Za Zhi, 2015, 37(9):676-81. http://cdmd.cnki.com.cn/Article/CDMD-10246-1013102698.htm
|
| [8] |
Nutting CM, Morden JP, Harrington KJ. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT):a phase 3 multicentre randomised controlled trial[J]. Lancet Oncol, 2011, 12(2):127-36. doi: 10.1016/S1470-2045(10)70290-4
|
| [9] |
Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11:a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J]. J Clin Oncol, 2013, 31(7):845-52. doi: 10.1200/JCO.2012.43.6097
|
| [10] |
Nwizu T, Ghi MG, Cohen EE, et al. The Role of Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma[J]. Semin Radia Oncol, 2012, 22(3):198-206. doi: 10.1016/j.semradonc.2012.03.004
|
| [11] |
Specenier PM, Vermorken JB. Recurrent head and neck cancer:current treatment and future prospects[J]. Expert Rev Anticancer Ther, 2008, 8(3):375-91. doi: 10.1586/14737140.8.3.375
|
| [12] |
杨柳青, 秦叔逵.第3代铂类药物洛铂的研究新进展[J].临床肿瘤学杂志, 2009, 14(12):1134-9. doi: 10.3969/j.issn.1009-0460.2009.12.019
Yang LQ, Qin SK. Progression of lobaplatin as the third generation platinum drug[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2009, 14(12):1134-9. doi: 10.3969/j.issn.1009-0460.2009.12.019
|
| [13] |
陈文玲, 朱严冰. 洛铂对喉癌细胞株Hep-2作用的初步探讨[D]. 河北: 河北医科大学, 2008.
Chen WL, Zhu YB. The initial approach on effect of lobaplation in laryngeal carcinoma cell line-Hep-2[D]. Hebei:Hebei Yi Ke Da Xue, 2008.
|
| [14] |
黄勇, 秦叔逵.洛铂治疗非小细胞肺癌的实验与临床研究现状及进展[J].临床肿瘤学杂志, 2015, 20(10):937-42. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201510017.htm
Huang Y, Qin SK. Experimental and clinical current situation and progress of lobaplatin in the treatment of non-small cell lung cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2015, 20(10):937-42. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201510017.htm
|
| [15] |
Peng Y, Liu JK, Lin Q. Clinical progression of lobaplatin in combination chemotherapy for patients with recurrence or metastatic cancer[J]. Chinese-German J Clin Oncol, 2014, 13(8):386-91.
|
| [16] |
尤涛, 赵微, 党雪菲.局部晚期鼻咽癌放疗同期洛铂化疗与顺铂化疗的比较研究[J].中国医药指南, 2015, 13(12):90. http://youxian.cnki.com.cn/yxdetail.aspx?filename=ZLFY20171027009&dbname=CAPJ2015
You T, Zhao W, Dang XF. A comparative study of concurrent radiotherapy plus platinum chemotherapy versus radiotherapy plus cisplatin chemotherapy for locally advanced nasopharyngeal carcinoma[J]. Zhongguo Yi Yao Zhi Nan, 2015, 13(12):90. http://youxian.cnki.com.cn/yxdetail.aspx?filename=ZLFY20171027009&dbname=CAPJ2015
|
| [17] |
Chen L, Hu CS, Chen XZ, et al. Concurrent, chemoradiatherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyneal carcinoma phase 3 multioentre randomized controlled trial[J]. Lancet Oncol, 2012, 13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: